as of 12-12-2025 3:35pm EST
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | CINCINNATI |
| Market Cap: | 13.4B | IPO Year: | 2016 |
| Target Price: | $465.18 | AVG Volume (30 days): | 265.4K |
| Analyst Decision: | Hold | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 14.32 | EPS Growth: | 25.36 |
| 52 Week Low/High: | $250.05 - $626.25 | Next Earning Date: | 10-22-2025 |
| Revenue: | $2,358,373,000 | Revenue Growth: | 13.88% |
| Revenue Growth (this year): | 21.48% | Revenue Growth (next year): | 11.90% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Avg Cost/Share
$590.69
Shares
668
Total Value
$394,580.92
Owned After
646,184
SEC Form 4
Avg Cost/Share
$590.47
Shares
5,698
Total Value
$3,364,498.06
Owned After
646,184
SEC Form 4
Avg Cost/Share
$593.25
Shares
23,178
Total Value
$13,750,348.50
Owned After
646,184
SEC Form 4
Avg Cost/Share
$593.46
Shares
15,151
Total Value
$8,991,512.46
Owned After
646,184
SEC Form 4
Avg Cost/Share
$606.88
Shares
41,331
Total Value
$25,082,957.28
Owned After
646,184
SEC Form 4
Avg Cost/Share
$615.52
Shares
42,392
Total Value
$26,093,123.84
Owned After
646,184
SEC Form 4
Avg Cost/Share
$607.78
Shares
59,025
Total Value
$35,874,214.50
Owned After
646,184
SEC Form 4
Exec. VP, Operations
Avg Cost/Share
$609.15
Shares
20,000
Total Value
$12,183,000.00
Owned After
27,500
SEC Form 4
Avg Cost/Share
$592.18
Shares
21,858
Total Value
$12,943,870.44
Owned After
646,184
SEC Form 4
CFO & Treasurer
Avg Cost/Share
$590.35
Shares
3,000
Total Value
$1,771,050.00
Owned After
6,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Troendle August J. | MEDP | CEO | Dec 3, 2025 | Sell | $590.69 | 668 | $394,580.92 | 646,184 | |
| Troendle August J. | MEDP | CEO | Dec 2, 2025 | Sell | $590.47 | 5,698 | $3,364,498.06 | 646,184 | |
| Troendle August J. | MEDP | CEO | Dec 1, 2025 | Sell | $593.25 | 23,178 | $13,750,348.50 | 646,184 | |
| Troendle August J. | MEDP | CEO | Nov 28, 2025 | Sell | $593.46 | 15,151 | $8,991,512.46 | 646,184 | |
| Troendle August J. | MEDP | CEO | Nov 26, 2025 | Sell | $606.88 | 41,331 | $25,082,957.28 | 646,184 | |
| Troendle August J. | MEDP | CEO | Nov 25, 2025 | Sell | $615.52 | 42,392 | $26,093,123.84 | 646,184 | |
| Troendle August J. | MEDP | CEO | Nov 24, 2025 | Sell | $607.78 | 59,025 | $35,874,214.50 | 646,184 | |
| BURWIG SUSAN E | MEDP | Exec. VP, Operations | Nov 24, 2025 | Sell | $609.15 | 20,000 | $12,183,000.00 | 27,500 | |
| Troendle August J. | MEDP | CEO | Nov 21, 2025 | Sell | $592.18 | 21,858 | $12,943,870.44 | 646,184 | |
| Brady Kevin M. | MEDP | CFO & Treasurer | Nov 21, 2025 | Sell | $590.35 | 3,000 | $1,771,050.00 | 6,000 |
MEDP Breaking Stock News: Dive into MEDP Ticker-Specific Updates for Smart Investing
See how MEDP stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "MEDP Medpace Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.